Becton Dickinson and (BDX)
NYSE: BDX
· Real-Time Price · USD
170.04
-2.06 (-1.20%)
At close: Jun 17, 2025, 10:02 AM
Becton Dickinson and Revenue Breakdown
| Period Ending | Sep 30, 2024 | Sep 30, 2023 | Sep 30, 2022 | Sep 30, 2021 | Sep 30, 2020 | Sep 30, 2019 | Sep 30, 2018 | Sep 30, 2017 | Sep 30, 2016 | Sep 30, 2015 | Sep 30, 2014 | Sep 30, 2013 | Sep 30, 2012 | Sep 30, 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interventional Revenue | 4.98B | 5.13B | 4.46B | 4.24B | 3.76B | 3.93B | 3.04B | 3.99B | 3.83B | 6.46B | 4.57B | 4.31B | 4.09B | 4.01B |
| Interventional Revenue Growth | -2.98% | +14.99% | +5.31% | +12.68% | -4.18% | +29.27% | -23.85% | +4.15% | -40.73% | +41.26% | +6.20% | +5.26% | +2.08% | n/a |
| Life Sciences Revenue | 5.19B | 4.29B | 5.56B | 6.53B | 4.67B | 4.3B | 4.33B | 8.11B | 8.65B | 3.82B | n/a | n/a | n/a | n/a |
| Life Sciences Revenue Growth | +20.92% | -22.84% | -14.79% | +39.68% | +8.72% | -0.69% | -46.58% | -6.34% | +126.43% | n/a | n/a | n/a | n/a | n/a |
| Medical Revenue | 10.07B | 1.86B | 8.84B | 9.48B | 8.68B | 9.06B | 8.62B | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Medical Revenue Growth | +440.16% | -78.91% | -6.73% | +9.21% | -4.24% | +5.20% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Revenue by Geography
| Period Ending | Sep 30, 2024 | Sep 30, 2023 | Sep 30, 2022 | Sep 30, 2021 | Sep 30, 2020 | Sep 30, 2019 | Sep 30, 2018 | Sep 30, 2017 | Sep 30, 2016 | Sep 30, 2015 | Sep 30, 2014 | Sep 30, 2013 | Sep 30, 2012 | Sep 30, 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asia Revenue | 2.91B | 2.91B | 3.05B | 3.27B | 2.57B | 2.73B | 2.46B | 1.74B | 1.69B | 1.54B | 1.12B | 1.01B | 883.29M | 684.32M |
| Asia Revenue Growth | -0.24% | -4.40% | -6.88% | +27.41% | -5.80% | +10.81% | +41.06% | +3.07% | +9.51% | +37.82% | +11.43% | +13.89% | +29.08% | n/a |
| Europe Revenue | 4.4B | 4.24B | 4.04B | 4.75B | 3.48B | 3.36B | 3.3B | 2.59B | 3.05B | 2.43B | 2.73B | 2.51B | 2.38B | 2.39B |
| Europe Revenue Growth | +3.72% | +4.97% | -14.90% | +36.52% | +3.60% | +1.85% | +27.43% | -15.12% | +25.27% | -10.94% | +8.80% | +5.60% | -0.34% | n/a |
| Others Country Revenue | 1.21B | 1.1B | 1.06B | 1.25B | 1.35B | 1.48B | 1.46B | 1.26B | 849M | 1.23B | 1.18B | 1.18B | 1.16B | 1.01B |
| Others Country Revenue Growth | +9.53% | +4.16% | -15.70% | -7.24% | -8.33% | +1.30% | +15.91% | +48.06% | -31.20% | +5.02% | -0.68% | +2.10% | +14.21% | n/a |
| United States Revenue | 11.66B | 11.11B | 10.72B | 10.97B | 9.72B | 9.73B | 8.77B | 6.5B | 6.89B | 5.07B | 3.42B | 3.35B | 3.29B | 3.29B |
| United States Revenue Growth | +4.95% | +3.65% | -2.25% | +12.90% | -0.14% | +10.97% | +34.81% | -5.64% | +35.98% | +48.35% | +1.91% | +1.99% | +0.03% | n/a |
Operating Expense Breakdown
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 1.27B | 1.32B | 1.26B | 1.2B | 1.19B | 1.21B | 1.14B | 1.19B | 1.21B | 1.19B | 1.18B | 1.15B | 1.23B | 1.19B | 1.33B | 1.24B | 1.15B | 1.15B | 1.2B | 980M | 1.02B | 1.12B | 1.09B | 1.08B | 1.09B | 1.07B | 1.1B | 1.08B | 1.06B | 774M | 774M | 719M | 724M | 709M | 796M | 728M | 732M | 748M | 756M | 764M | 511M |
| Selling, General, and Administrative Revenue Growth | -3.41% | +4.94% | +5.02% | +0.25% | -1.65% | +6.68% | -4.45% | -1.24% | +1.52% | +0.42% | +2.87% | -6.74% | +3.97% | -11.04% | +7.68% | +7.75% | -0.09% | -4.25% | +22.45% | -4.39% | -8.56% | +2.47% | +1.67% | -1.19% | +1.49% | -2.72% | +2.04% | +2.27% | +36.56% | 0.00% | +7.65% | -0.69% | +2.12% | -10.93% | +9.34% | -0.55% | -2.14% | -1.06% | -1.05% | +49.51% | n/a |
| Research and Development Revenue | 302M | 343M | 302M | 299M | 299M | 290M | 281M | 306M | 337M | 313M | 300M | 315M | 343M | 314M | 387M | 344M | 317M | 291M | 299M | 262M | 264M | 270M | 270M | 282M | 252M | 258M | 278M | 277M | 260M | 192M | 221M | 186M | 187M | 182M | 253M | 207M | 182M | 187M | 196M | 178M | 129M |
| Research and Development Revenue Growth | -11.95% | +13.58% | +1.00% | 0.00% | +3.10% | +3.20% | -8.17% | -9.20% | +7.67% | +4.33% | -4.76% | -8.16% | +9.24% | -18.86% | +12.50% | +8.52% | +8.93% | -2.68% | +14.12% | -0.76% | -2.22% | 0.00% | -4.26% | +11.90% | -2.33% | -7.19% | +0.36% | +6.54% | +35.42% | -13.12% | +18.82% | -0.53% | +2.75% | -28.06% | +22.22% | +13.74% | -2.67% | -4.59% | +10.11% | +37.98% | n/a |